Peter A. Thompson - 27 Jun 2025 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: CRVS
Reported as of: 27 Jun 2025
Net transaction value: -$0.2552
SEC form: 4
Accepted by SEC: 01 Jul 2025, 21:17:05 UTC
Prior SEC filing: 27 Jun 2025
Next SEC filing: 26 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter A. Thompson

Key filing fact

Peter A. Thompson filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 01 Jul 2025.

Key facts

This page summarizes Peter A. Thompson's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Jul 2025, 21:17.

Change

Previous filing in this sequence was filed on 27 Jun 2025.
Current net transaction value: -$0.2552.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001357522 Primary reporting owner

Thompson Peter A.

Relationship: Director, 10%+ Owner
Address: C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Peter A. Thompson
Signature date: 01 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRVS transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value: $4,891,894
Shares: +1,397,684
Change %: +20%
Price: $3.50
Shares after: 8,341,338
Date: 27 Jun 2025
Ownership: See Footnotes
Footnotes: F2, F3

CRVS transaction

Common Stock

Sale

Transaction value: $4,891,894
Shares: -1,176,332
Change %: -14%
Price: $4.16
Shares after: 7,165,006
Date: 27 Jun 2025
Ownership: See Footnotes
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVS transaction Derivative

Common Warrants (right to buy)

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -1,397,684
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 27 Jun 2025
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 1,397,684
Exercise price: $3.50
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares.

Footnote F2

These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.

Footnote F3

Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.